ifosfamide has been researched along with Disease Models, Animal in 35 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells." | 7.81 | Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium." | 7.77 | Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011) |
| "Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)." | 7.72 | Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003) |
| "Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy." | 5.51 | Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. ( Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | 5.37 | Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "In this study, ifosfamide-loaded poly (lactic-co-glycolic acid) (PLGA)-dextran polymeric nanoparticles (PD/IFS) was developed and studied its anticancer efficacy against multiple osteosarcoma cancer cells." | 3.81 | Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma. ( Chen, B; Lin, XJ; Wang, LF; Yang, JZ; Zhang, YJ, 2015) |
| "This study investigated whether cyclophosphamide (CP) and ifosfamide (IFO) therapy alters the expression of the key genes engaged in long-chain fatty acid (LCFA) oxidation outside rat heart mitochondria, and if so, whether these alterations should be viewed as a mechanism during CP- and IFO-induced cardiotoxicity." | 3.80 | Inhibition of gene expression of carnitine palmitoyltransferase I and heart fatty acid binding protein in cyclophosphamide and ifosfamide-induced acute cardiotoxic rat models. ( Al-Harbi, MM; Al-Harbi, NO; Al-Hosaini, KA; Al-Shabanah, OA; Al-Sharary, SD; Aldelemy, ML; Hafez, MM; Sayed-Ahmed, MM, 2014) |
| "Ifosfamide (IFS) is often involved in the occurrence of hemorrhagic cystitis due to direct contact of its metabolite acrolein with uroepithelium." | 3.77 | Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder. ( Brito, GA; Jucá, DM; Lima, RC; Macedo, FY; Magalhães, PJ; Mourão, LT; Neto, Jde S; Palheta, RC; Ribeiro, RA; Santos, AA; Souza, MH, 2011) |
| "Hemorrhagic cystitis (HC) is a limiting side-effect of chemotherapy with ifosfamide (IFS)." | 3.72 | Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis. ( Belarmino-Filho, JN; Brito, GA; Cunha, FQ; Macedo, FY; Nery, EA; Ribeiro, RA; Vieira, MM, 2003) |
| "Ifosfamide (IFO) is an alkylating agent administered against different types of malignancies." | 1.56 | The Nephroprotective Role of Carnosine Against Ifosfamide-Induced Renal Injury and Electrolytes Imbalance is Mediated Via the Regulation of Mitochondrial Function and Alleviation of Oxidative Stress. ( Farshad, O; Ghanbarinejad, V; Heidari, R; Ilkhaninasab, F; Khadijeh, M; Moezi, L; Mohammadi, HR; Negar, A; Ommati, MM; Zahra, M, 2020) |
| "Novel therapeutic options to treat hemorrhagic cystitis are needed." | 1.51 | IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis. ( Akinwale, J; Alouffi, A; Falcone, FH; Hsieh, MH; Jardetzky, TS; Le, LH; Mbanefo, EC; Odegaard, JI; Pennington, LF; Zee, RS, 2019) |
| "Olaratumab (OLA), a monoclonal antibody against platelet-derived growth factor receptor alpha (PDGFRα), has recently been used against soft-tissue sarcoma (STS) combined with doxorubicin (DOX), with limited efficacy." | 1.51 | Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model. ( Bouvet, M; Hayashi, K; Higuchi, T; Hoffman, RM; Igarashi, K; Kimura, H; Miwa, S; Miyake, K; Oshiro, H; Razmjooei, S; Singh, SR; Sugisawa, N; Tsuchiya, H; Yamamoto, N; Zhang, Z, 2019) |
| "Ifosfamide is an anticancer agent used largely in treatment of solid tumors." | 1.43 | Antioxidant activity of simvastatin prevents ifosfamide-induced nephrotoxicity. ( Ali, RM; Alkaraki, AK; Mhaidat, NM; Shotar, AM, 2016) |
| " The novel dosing strategy for cyclophosphamide described herein is readily translatable to standard clinical regimens, represents a potentially significant advance in addressing the drug delivery challenge, and may have broad applicability for nanomedicines." | 1.42 | Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302). ( De Souza, R; Dumont, N; Espelin, CW; Gaddy, DF; Geretti, E; Hendriks, BS; Jaffray, DA; Lee, H; Leonard, SC; Moyo, V; Nielsen, UB; Wickham, TJ; Zheng, J, 2015) |
| "Osteosarcoma is the first primary malignant bone tumor, characterized by a complex genetic and resistance to conventional treatments." | 1.37 | Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. ( Alberti, L; Besse, A; Blay, JY; Duc, A; Dutour, A; Gougelet, A; Perez, J; Pissaloux, D, 2011) |
| "Neutropenia is the most common collateral effect of chemotherapy." | 1.37 | Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells. ( Alvarez-Silva, M; Asbahr, AC; Benedetti, AL; Bertol, G; Dalmora, SL; do Carmo Araújo, M; Farias, I; Farias, J; Schetinger, MR; Zimmermann, ES, 2011) |
| "Ifosfamide nephrotoxicity is a serious adverse effect for children undergoing cancer chemotherapy." | 1.35 | N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats. ( Aleksa, K; Chen, N; Koren, G; Rieder, M; Woodland, C, 2008) |
| "treatment with ifosfamide alone or ifosfamide combined with microencapsulated CYP2B1 expressing cells." | 1.34 | Targeted intraabdominal chemotherapy for peritoneal carcinomatosis. ( Löhr, M; Samel, S, 2007) |
| "Here we show that ethanol withdrawal symptoms were completely absent in cannabinoid CB1 receptor-deficient mice, although acute effects of ethanol and ethanol tolerance and preference were basically normal." | 1.32 | A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking. ( Bilkei-Gorzo, A; Michel, K; Palkovits, M; Racz, I; Toth, ZE; Zimmer, A, 2003) |
| " The in vivo modulation of these alternative, competing pathways of P-450 metabolism was investigated in pharmacokinetic studies carried out in the rat model." | 1.30 | In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity. ( Brain, EG; Drewes, P; Gustafsson, K; Hecht, JE; Waxman, DJ; Yu, LJ, 1999) |
| "The prognosis of pancreatic cancer is poor, and current medical treatment is mostly ineffective." | 1.30 | Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors. ( Günzburg, WH; Jesnowski, R; Karle, P; Liebe, S; Löhr, M; Müller, P; Nizze, H; Püschel, K; Renz, R; Saller, R; Salmons, B; Stein, H; von Rombs, K; Wagner, T, 1999) |
| "Emesis was characterized by expulsion of solid or liquid material." | 1.29 | Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents. ( Göthert, M; Herold, H; Szelenyi, I, 1994) |
| " Dose-response curves for cisplatin (3-30 000 nmol) combined with non-toxic silibinin doses (7." | 1.29 | Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. ( Bokemeyer, C; Dunn, T; Fels, LM; Gaedeke, J; Lentzen, H; Schmoll, HJ; Stolte, H; Voigt, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.86) | 18.7374 |
| 1990's | 8 (22.86) | 18.2507 |
| 2000's | 9 (25.71) | 29.6817 |
| 2010's | 14 (40.00) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Ommati, MM | 1 |
| Farshad, O | 1 |
| Ghanbarinejad, V | 1 |
| Mohammadi, HR | 1 |
| Khadijeh, M | 1 |
| Negar, A | 1 |
| Zahra, M | 1 |
| Ilkhaninasab, F | 1 |
| Moezi, L | 1 |
| Heidari, R | 1 |
| Kiani, A | 1 |
| Nik, SH | 1 |
| Khodadoost, A | 1 |
| Salimi, A | 1 |
| Pourahmad, J | 1 |
| Dunsmore, G | 1 |
| Koleva, P | 1 |
| Ghobakhloo, N | 1 |
| Sutton, R | 1 |
| Ambrosio, L | 1 |
| Meng, X | 1 |
| Hotte, N | 1 |
| Nguyen, V | 1 |
| Madsen, KL | 1 |
| Dieleman, LA | 1 |
| Huang, V | 1 |
| Elahi, S | 1 |
| Zee, RS | 1 |
| Mbanefo, EC | 1 |
| Le, LH | 1 |
| Pennington, LF | 1 |
| Odegaard, JI | 1 |
| Jardetzky, TS | 1 |
| Alouffi, A | 1 |
| Akinwale, J | 1 |
| Falcone, FH | 1 |
| Hsieh, MH | 1 |
| Higuchi, T | 1 |
| Miyake, K | 1 |
| Sugisawa, N | 1 |
| Oshiro, H | 1 |
| Zhang, Z | 1 |
| Razmjooei, S | 1 |
| Yamamoto, N | 1 |
| Hayashi, K | 1 |
| Kimura, H | 1 |
| Miwa, S | 1 |
| Igarashi, K | 1 |
| Bouvet, M | 1 |
| Singh, SR | 1 |
| Tsuchiya, H | 1 |
| Hoffman, RM | 1 |
| Sayed-Ahmed, MM | 2 |
| Aldelemy, ML | 2 |
| Al-Shabanah, OA | 2 |
| Hafez, MM | 2 |
| Al-Hosaini, KA | 2 |
| Al-Harbi, NO | 2 |
| Al-Sharary, SD | 1 |
| Al-Harbi, MM | 2 |
| Yu, CL | 1 |
| Zhou, H | 1 |
| Chai, AP | 1 |
| Yang, YX | 1 |
| Mao, RR | 1 |
| Xu, L | 1 |
| Geretti, E | 1 |
| Leonard, SC | 1 |
| Dumont, N | 1 |
| Lee, H | 1 |
| Zheng, J | 1 |
| De Souza, R | 1 |
| Gaddy, DF | 1 |
| Espelin, CW | 1 |
| Jaffray, DA | 1 |
| Moyo, V | 1 |
| Nielsen, UB | 1 |
| Wickham, TJ | 1 |
| Hendriks, BS | 1 |
| Chen, B | 1 |
| Yang, JZ | 1 |
| Wang, LF | 1 |
| Zhang, YJ | 1 |
| Lin, XJ | 1 |
| Mhaidat, NM | 1 |
| Ali, RM | 1 |
| Shotar, AM | 1 |
| Alkaraki, AK | 1 |
| Macedo, FY | 2 |
| Mourão, LT | 2 |
| Palheta, RC | 1 |
| Jucá, DM | 1 |
| Lima, RC | 1 |
| Neto, Jde S | 1 |
| Magalhães, PJ | 2 |
| Santos, AA | 1 |
| Souza, MH | 1 |
| Brito, GA | 2 |
| Ribeiro, RA | 3 |
| Gougelet, A | 1 |
| Pissaloux, D | 1 |
| Besse, A | 1 |
| Perez, J | 1 |
| Duc, A | 1 |
| Dutour, A | 1 |
| Blay, JY | 1 |
| Alberti, L | 1 |
| Farias, I | 1 |
| do Carmo Araújo, M | 1 |
| Zimmermann, ES | 1 |
| Dalmora, SL | 1 |
| Benedetti, AL | 1 |
| Alvarez-Silva, M | 1 |
| Asbahr, AC | 1 |
| Bertol, G | 1 |
| Farias, J | 1 |
| Schetinger, MR | 1 |
| de Siqueira, RJ | 1 |
| Freire, WB | 1 |
| Vasconcelos-Silva, AA | 1 |
| Fonseca-Magalhães, PA | 1 |
| Lima, FJ | 1 |
| Brito, TS | 1 |
| Lahlou, S | 1 |
| Hlavaty, J | 1 |
| Petznek, H | 1 |
| Holzmüller, H | 1 |
| Url, A | 1 |
| Jandl, G | 1 |
| Berger, A | 1 |
| Salmons, B | 2 |
| Günzburg, WH | 2 |
| Renner, M | 1 |
| Aleisa, AM | 1 |
| Al-Rejaie, SS | 1 |
| Racz, I | 1 |
| Bilkei-Gorzo, A | 1 |
| Toth, ZE | 1 |
| Michel, K | 1 |
| Palkovits, M | 1 |
| Zimmer, A | 1 |
| Vieira, MM | 1 |
| Belarmino-Filho, JN | 1 |
| Nery, EA | 1 |
| Cunha, FQ | 1 |
| Aleksa, K | 2 |
| Halachmi, N | 1 |
| Ito, S | 1 |
| Koren, G | 2 |
| Indrová, M | 1 |
| Bieblová, J | 1 |
| Jandlová, T | 1 |
| Vonka, V | 1 |
| Pajtasz-Piasecka, E | 1 |
| Reinis, M | 1 |
| Laurie, C | 1 |
| Reynolds, A | 1 |
| Coskun, O | 1 |
| Bowman, E | 1 |
| Gendelman, HE | 1 |
| Mosley, RL | 1 |
| Samel, S | 1 |
| Löhr, M | 2 |
| Chen, N | 1 |
| Woodland, C | 1 |
| Rieder, M | 1 |
| Osieka, R | 1 |
| Pohl, J | 1 |
| Bertram, B | 1 |
| Hilgard, P | 1 |
| Nowrousian, MR | 1 |
| Stüben, J | 1 |
| Wiessler, M | 1 |
| Szelenyi, I | 1 |
| Herold, H | 1 |
| Göthert, M | 1 |
| Zamlauski-Tucker, MJ | 1 |
| Morris, ME | 1 |
| Springate, JE | 1 |
| Bokemeyer, C | 1 |
| Fels, LM | 1 |
| Dunn, T | 1 |
| Voigt, W | 1 |
| Gaedeke, J | 1 |
| Schmoll, HJ | 1 |
| Stolte, H | 1 |
| Lentzen, H | 1 |
| Yu, LJ | 1 |
| Drewes, P | 1 |
| Gustafsson, K | 1 |
| Brain, EG | 1 |
| Hecht, JE | 1 |
| Waxman, DJ | 1 |
| Müller, P | 1 |
| Jesnowski, R | 1 |
| Karle, P | 1 |
| Renz, R | 1 |
| Saller, R | 1 |
| Stein, H | 1 |
| Püschel, K | 1 |
| von Rombs, K | 1 |
| Nizze, H | 1 |
| Liebe, S | 1 |
| Wagner, T | 1 |
| Sommer, K | 1 |
| Peters, SO | 1 |
| Robins, IH | 1 |
| Raap, M | 1 |
| Wiedemann, GJ | 1 |
| Remmert, S | 1 |
| Sieg, P | 1 |
| Bittner, C | 1 |
| Feyerabend, T | 1 |
| Lichtenberg, J | 1 |
| Larsson, LI | 1 |
| Chauffert, B | 1 |
| Dimanche-Boitrel, MT | 1 |
| Genne, P | 1 |
| Petit, JM | 1 |
| Onier, N | 1 |
| Jeannin, JF | 1 |
| Martens, AC | 1 |
| de Groot, CJ | 1 |
| Hagenbeek, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Diagnostic Value and Biological Significant of cd71 in Lymphoid Dis Order[NCT03720977] | 139 participants (Anticipated) | Observational | 2019-12-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
35 other studies available for ifosfamide and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
The Nephroprotective Role of Carnosine Against Ifosfamide-Induced Renal Injury and Electrolytes Imbalance is Mediated Via the Regulation of Mitochondrial Function and Alleviation of Oxidative Stress.
Topics: Acute Kidney Injury; Animals; Antineoplastic Agents, Alkylating; Antioxidants; Carnosine; Disease Mo | 2020 |
Trifluoperazine an Antipsychotic Drug and Inhibitor of Mitochondrial Permeability Transition Protects Cytarabine and Ifosfamide-Induced Neurotoxicity.
Topics: Animals; Antineoplastic Agents; Brain; Cells, Cultured; Cytarabine; Disease Models, Animal; Humans; | 2020 |
Lower Abundance and Impaired Function of CD71+ Erythroid Cells in Inflammatory Bowel Disease Patients During Pregnancy.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease Models, An | 2019 |
IPSE, a parasite-derived host immunomodulatory protein, is a potential therapeutic for hemorrhagic cystitis.
Topics: Administration, Intravesical; Animals; Basophils; Cell Line; Cell Proliferation; Cystitis; Disease M | 2019 |
Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Disease Models, Ani | 2019 |
Inhibition of gene expression of carnitine palmitoyltransferase I and heart fatty acid binding protein in cyclophosphamide and ifosfamide-induced acute cardiotoxic rat models.
Topics: Animals; Antineoplastic Agents, Alkylating; Blotting, Western; Cardiomyopathies; Cardiotoxicity; Car | 2014 |
Whole-scale neurobehavioral assessments of photothrombotic ischemia in freely moving mice.
Topics: Analysis of Variance; Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Infarction; Bra | 2015 |
Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302).
Topics: Animals; Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclophosphamid | 2015 |
Ifosfamide-loaded poly (lactic-co-glycolic acid) PLGA-dextran polymeric nanoparticles to improve the antitumor efficacy in Osteosarcoma.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Bone Neoplasms; Caspase 3; Cell Line, Tumor; | 2015 |
Antioxidant activity of simvastatin prevents ifosfamide-induced nephrotoxicity.
Topics: Animals; Antioxidants; Biomarkers; Creatinine; Cytoprotection; Disease Models, Animal; Ifosfamide; K | 2016 |
Cyclooxygenase-2 contributes to functional changes seen on experimental hemorrhagic cystitis induced by ifosfamide in rat urinary bladder.
Topics: Animals; Antineoplastic Agents, Alkylating; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cystitis; | 2011 |
Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response.
Topics: Animals; Antineoplastic Agents; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Disease Models, Animal | 2011 |
Uncaria tomentosa stimulates the proliferation of myeloid progenitor cells.
Topics: Administration, Oral; Animals; Cat's Claw; Cell Proliferation; Cells, Cultured; Disease Models, Anim | 2011 |
In-vitro characterization of the pharmacological effects induced by (-)-α-bisabolol in rat smooth muscle preparations.
Topics: Animals; Carbachol; Cystitis; Disease Models, Animal; Duodenum; Ifosfamide; In Vitro Techniques; Inf | 2012 |
Evaluation of a gene-directed enzyme-product therapy (GDEPT) in human pancreatic tumor cells and their use as in vivo models for pancreatic cancer.
Topics: Animals; Biomarkers, Tumor; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzym | 2012 |
Downregulation of oxidative and nitrosative apoptotic signaling by L-carnitine in Ifosfamide-induced Fanconi syndrome rat model.
Topics: Animals; Apoptosis; Blood Urea Nitrogen; Carnitine; Caspases; Catalase; Creatinine; Disease Models, | 2012 |
A critical role for the cannabinoid CB1 receptors in alcohol dependence and stress-stimulated ethanol drinking.
Topics: Alcohol Drinking; Alcoholism; Animals; Antineoplastic Combined Chemotherapy Protocols; Ataxia; Behav | 2003 |
Use of dexamethasone with mesna for the prevention of ifosfamide-induced hemorrhagic cystitis.
Topics: Animals; Anti-Inflammatory Agents; Cystitis; Dexamethasone; Disease Models, Animal; Dose-Response Re | 2003 |
Renal ontogeny of ifosfamide nephrotoxicity.
Topics: Acetaldehyde; Age Factors; Animals; Antineoplastic Agents, Alkylating; Aryl Hydrocarbon Hydroxylases | 2004 |
Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Topics: Animals; Cancer Vaccines; Disease Models, Animal; Down-Regulation; Genes, MHC Class I; Genetic Thera | 2006 |
CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adoptive Transfer; Animals; Antineoplastic Combined Ch | 2007 |
Targeted intraabdominal chemotherapy for peritoneal carcinomatosis.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents, Alkylating; Carcinoma; Cell Line, Tumor; Ce | 2007 |
N-Acetylcysteine prevents ifosfamide-induced nephrotoxicity in rats.
Topics: Acetylcysteine; Animals; Antineoplastic Agents, Alkylating; beta 2-Microglobulin; Creatinine; Diseas | 2008 |
Studies on drug resistance in a human melanoma xenograft system.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Disease Models, Ani | 1984 |
D-19575--a sugar-linked isophosphoramide mustard derivative exploiting transmembrane glucose transport.
Topics: Absorption; Administration, Oral; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Ce | 1995 |
Emesis induced in domestic pigs: a new experimental tool for detection of antiemetic drugs and for evaluation of emetogenic potential of new anticancer agents.
Topics: Animals; Antiemetics; Antineoplastic Agents; Carboplatin; Cisplatin; Cyclophosphamide; Dactinomycin; | 1994 |
Ifosfamide metabolite chloroacetaldehyde causes Fanconi syndrome in the perfused rat kidney.
Topics: Absorption; Acetaldehyde; Acrolein; Animals; Chemotherapy, Cancer, Regional Perfusion; Disease Model | 1994 |
Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cisplatin; Disease Models, A | 1996 |
In vivo modulation of alternative pathways of P-450-catalyzed cyclophosphamide metabolism: impact on pharmacokinetics and antitumor activity.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Brain Neoplasms; Cyclophosphamide; Cytochrome P-45 | 1999 |
Injection of encapsulated cells producing an ifosfamide-activating cytochrome P450 for targeted chemotherapy to pancreatic tumors.
Topics: Animals; Antineoplastic Agents, Alkylating; Capsules; Cell Line; Cytochrome P-450 CYP2B1; Disease Mo | 1999 |
A preclinical model for experimental chemotherapy of human head and neck cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Platelets; Body Weight; Carboplatin; | 2001 |
A mouse model for the study of factors affecting angiogenesis.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Disease Models, Anima | 2002 |
[Experimental chemotherapy of peritoneal carcinomatosis of colonic origin in rats].
Topics: Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Disease Models, Anim | 1992 |
Development and characterisation of a cyclophosphamide resistant variant of the BNML rat model for acute myelocytic leukaemia.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclophosphamide; Disease Models, Animal; Dose-Response R | 1991 |